Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).

被引：0
|
作者：
Schonhoft, Joseph
Gill, Audrey
Graf, Ryon P.
Jendrisak, Adam
Barnett, Ethan
Benoliel, Hannah
Carbone, Emily
Tubbs, Alisa
Orr, Sarah
Byun, Jiyun
Wenstrup, Rick
Scher, Howard, I
机构：
[1] Epic Sci Inc, San Diego, CA USA
[2] Epic Sci, San Diego, CA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5571
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] COST-UTILITY ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Vicente, C.
    Babashov, V
    Husein, F.
    Saad, F.
    Naidoo, S.
    Holmstrom, S.
    VALUE IN HEALTH, 2014, 17 (03) : A89 - A90
  • [23] Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Han, Xin
    Zhao, Lijie
    Xiang, Weiguo
    Qin, Chong
    Miao, Bukeyan
    Xu, Tianfeng
    Lu, Jianfeng
    Wang, Mi
    Wang, Shaomeng
    CANCER RESEARCH, 2020, 80 (16)
  • [24] Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer
    Csizmarik, Anita
    Hadaschik, Boris
    Kramer, Gero
    Nyirady, Peter
    Szarvas, Tibor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 728.e13 - 728.e24
  • [25] Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher, Howard, I
    Armstrong, Andrew J.
    Schonhoft, Joseph D.
    Gill, Audrey
    Zhao, Jimmy
    Barnett, Ethan
    Carbone, Emily
    Lu, James
    Antonarakis, Emmanuel S.
    Luo Jun
    Tagawa, Scott T.
    Yang Qian
    George, Daniel J.
    Szmulewitz, Russell Zelig
    Danila, Daniel Costin
    Wenstrup, Rick
    Gonen, Mithat
    Halabi, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza).
    Silberstein, John
    Luber, Brandon
    Wang, Hao
    Lu, Changxue
    Chen, Yan
    Zhu, Yezi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [27] Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
    Conteduca, Vincenza
    Castro, Elena
    Wetterskog, Daniel
    Scarpi, Emanuela
    Jayaram, Anuradha
    Romero-Laorden, Nuria
    Olmos, David
    Gurioli, Giorgia
    Lolli, Cristian
    Isabel Sacz, Maria
    Puente, Javier
    Schepisi, Giuseppe
    Salvi, Samanta
    Wingate, Anna
    Medina, Ana
    Querol-Ninerola, Rosa
    Marin-Aguilera, Mercedes
    Angel Arranz, Jose
    Fornarini, Giuseppe
    Basso, Umberto
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Attard, Gerhardt
    De Giorgi, Ugo
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 158 - 168
  • [28] CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
    De Bono, Johann S.
    Pantel, Klaus
    Efstathiou, Eleni
    Sternberg, Cora N.
    Castellano, Daniel
    Fizazi, Karim
    Tombal, Bertrand
    Wulfing, Christian
    Schonhoft, Joseph D.
    Gill, Audrey
    Chu, Lincy
    Wenstrup, Rick
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Mace, Sandrine
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).
    Romero, Gustavo Rubio
    Weinstein, Alana
    Friedl, Verena
    Foye, Adam
    Playdle, Denise
    Sabol, Alexis
    Li, Patricia
    Huang, Jiaoti
    Feng, Felix Y.
    Stuart, Joshua M.
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
    Gurioli, G.
    Conteduca, V.
    Brighi, N.
    Scarpi, E.
    Basso, U.
    Fornarini, G.
    Mosca, A.
    Nicodemo, M.
    Banna, G. L.
    Lolli, C.
    Schepisi, G.
    Ravaglia, G.
    Ulivi, P.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2021, 32 : S654 - S655
12345